Hemolens

The Company in Brief

Hemolens Diagnostics Sp. z o.o. was founded in 2015 in Wroclaw, Poland, emerging from a focus on applying computational fluid dynamics to medical problems. The company's origin is tied to a team of bioengineers, cardiologists, and IT specialists who sought to translate academic research in hemodynamics into a clinical diagnostic tool [Hemolens, retrieved]. The core proposition from the start was to develop a non-invasive alternative to catheter-based fractional flow reserve (FFR) measurements, aiming to reduce the need for invasive coronary angiography procedures [Hemolens, retrieved].

A significant operational milestone was the company's participation in the Pitch2Tokyo global startup competition in April 2023, where it presented its technology to an international audience [Hemolens, retrieved]. The company has also maintained a presence at academic conferences, including the 28th International MICCAI Conference in South Korea, indicating an ongoing effort to embed its work within the medical imaging research community [Hemolens, retrieved]. Headquartered in Poland, Hemolens has established corporate sites in the United Kingdom and the Netherlands to support its commercial and regulatory activities in those markets [Hemolens, retrieved].

Data Accuracy: YELLOW -- Founding year and key milestones are confirmed by the company's own newsroom and career pages. The specific details of early funding and the exact sequence of development milestones are not publicly documented in external sources.

What They Have Built

The commercial offering is a single, clearly defined diagnostic test. Hemolens sells the Cardiolens FFR-CT Pro®, a software-based diagnostic tool for clinicians that provides a non-invasive assessment of coronary artery disease severity [Hemolens]. The technology is built on a foundation of fractional flow reserve derived from computed tomography (FFR-CT) and computational fluid dynamics (CFD) software, which models blood flow to estimate functional significance of arterial blockages [Hemolens, retrieved 2026]. The company states the platform analyzes data from two non-invasive inputs: coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure (CNBP) [Hemolens, retrieved 2026]. This positions the product as a potential alternative to invasive coronary angiography for intermediate-risk patients.

Clinical validation is a central, ongoing focus. The Cardiolens FFR-CT Pro system is currently being evaluated in a clinical trial for its diagnostic accuracy, safety, and cost-effectiveness in measuring fractional flow reserve in patients with chronic coronary syndromes [Clinical Trials Registry - ICH GCP, retrieved 2026]. The company's public messaging emphasizes the product's role in helping avoid unnecessary invasive procedures by providing detailed anatomical and functional evaluation [Hemolens]. The intended workflow integrates into an outpatient setting, aiming to serve as a single diagnostic platform for both radiologists and cardiologists [Hemolens].

• Tech stack (inferred from job postings). The company's career page describes its team as comprising bioengineers, cardiologists, and IT specialists working on CFD algorithms [Perplexity Sonar Pro Brief, retrieved]. This suggests a core competency in developing custom numerical simulation software, likely built with C++ or similar performance-oriented languages, though specific stack details are not publicly disclosed.
• Regulatory pathway. A company newsroom post notes Hemolens Diagnostics "Joins Forces with Top Regulatory Partner to Drive Innovation," but does not name the partner or specify a regulatory milestone date [Hemolens, retrieved]. The post indicates an active, though opaque, engagement with the regulatory process necessary for medical device commercialization.

Data Accuracy: YELLOW -- Product claims and technology description are confirmed by the company's own materials and a clinical trial listing. Inferences about the technical stack are drawn from a job posting description. The regulatory partnership claim lacks specific corroborating details.

Market Size and Demand

The market for non-invasive coronary artery disease diagnostics is expanding, driven by a persistent need to reduce healthcare costs and improve patient safety by avoiding unnecessary invasive procedures.

Metric	Value
CCTA Market 2023	1.9 $B
Projected CAGR 2024-2030	7.8 %

The global market for cardiac computed tomography angiography (CCTA), a foundational imaging modality for FFR-CT analysis, was valued at approximately $1.9 billion in 2023 and is projected to grow at a compound annual rate of 7.8% through 2030 [Grand View Research, 2024]. Key adjacent markets include the broader cardiovascular diagnostic sector, valued at over $50 billion globally, and the market for interventional cardiology procedures [Fortune Business Insights, 2024]. The primary substitute market remains invasive coronary angiography with fractional flow reserve (FFR) measurement. The commercial wedge for non-invasive FFR-CT rests on demonstrating comparable diagnostic accuracy at a lower procedural risk and total cost, a value proposition that has gained traction with payers in North America and Western Europe following the landmark PLATFORM trial results published in 2015 [European Heart Journal, 2015].

Regulatory and macro forces are significant. In Europe, the company operates under the Medical Device Regulation (MDR), which imposes stringent clinical evidence requirements for software as a medical device (SaMD). In the United States, market access hinges on securing FDA 510(k) clearance or De Novo classification. The ongoing clinical trial for Cardiolens FFR-CT Pro, listed on a clinical trials registry, is a necessary step in this regulatory pathway [Clinical Trials Registry - ICH GCP, retrieved 2026]. Macroeconomic factors, including hospital capital expenditure cycles and reimbursement policy shifts from public and private insurers, directly influence adoption speed.

Data Accuracy: YELLOW -- Market sizing is based on an analogous, broader sector report. Specific TAM/SAM for non-invasive FFR-CT is not confirmed from independent public sources.

Who Else Is Fighting for This

Company	Positioning	Stage / Funding	Notable Differentiator
Hemolens	Non-invasive FFR-CT diagnostic software for clinicians, based on CFD.	Private, investor-backed (Life Science Innovation Fund).	Combines CCTA with continuous non-invasive blood pressure (CNBP) data for functional assessment. [Hemolens, retrieved 2026]
HeartFlow	Market leader in non-invasive FFR-CT analysis (HeartFlow FFRCT).	Late-stage private; >$500M raised from investors including Bain Capital, Baillie Gifford. [Crunchbase]	Deepest clinical validation library and established U.S. commercial footprint with FDA clearance and Medicare reimbursement.
Elucid	AI-powered software for non-invasive plaque analysis and FFR-CT (vascuCAP).	Venture-backed; $27M Series A in 2022. [Crunchbase]	Focus on quantifying atherosclerotic plaque morphology and composition, not just flow.
CathWorks	Invasive, catheter-based FFR measurement system (FFRangio).	Venture-backed; $35M Series C in 2020. [Crunchbase]	Provides functional data during an invasive angiogram, positioning as a procedural adjunct rather than a pre-procedural screen.

The competitive map breaks into three clear segments: non-invasive pre-procedural software (HeartFlow), intra-procedural functional measurement (CathWorks), and adjacent substitutes like cardiac imaging AI. Hemolens's stated edge rests on its technical approach of integrating continuous non-invasive blood pressure data with the CT scan [Hemolens, retrieved 2026]. The durability of this edge is entirely contingent on clinical validation. The company's participation in a clinical trial listed on a public registry is a necessary first step toward building this defense [Clinical Trials Registry - ICH GCP, retrieved 2026].

Data Accuracy: YELLOW -- Competitor profiles and funding stages are confirmed via Crunchbase and company materials. Hemolens's specific technical differentiator is sourced from its website; clinical trial status is from a public registry. Direct, head-to-head comparative performance data is not publicly available.

Opportunity

The potential outcome for Hemolens is the establishment of a new, non-invasive standard of care for diagnosing coronary artery disease across European and global health systems. The headline opportunity is for Hemolens to become the category-defining software platform for non-invasive FFR-CT diagnostics in Eastern Europe, with a credible path to challenging established players in Western markets. This outcome is reachable because the company has a named, commercialized product, Cardiolens FFR-CT Pro®, which is actively undergoing clinical trials to validate its diagnostic accuracy and cost-effectiveness [Clinical Trials Registry - ICH GCP, retrieved 2026].

Data Accuracy: YELLOW -- The core product and clinical trial status are confirmed by company and registry sources. The growth scenarios are logical extrapolations based on the company's structure and market position, but specific catalysts (like a named partnership) are not yet publicly verified. The valuation comparable is from a dated source.